×
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT

AstraZeneca's cancer drug fails to meet main goal in Covid-19 trials

It remained committed to its clinical trials for its Covid-19 vaccine, developed in partnership with Oxford University
Last Updated : 12 November 2020, 08:17 IST
Last Updated : 12 November 2020, 08:17 IST

Follow Us :

Comments

AstraZeneca Plc said on Thursday its blood cancer treatment, Calquence, failed to meet the main goal of mid-stage trials, testing it in patients hospitalised with respiratory symptoms of Covid-19.

The drugmaker called the results from the study disappointing but said it remained committed to its clinical trials for its Covid-19 vaccine, developed in partnership with Oxford University, and its long-acting antibody combination.

Results from the trials will not impact approved indications or pending approvals for Calquence in patients with blood cancers, the company said.

ADVERTISEMENT
Published 12 November 2020, 08:17 IST

Deccan Herald is on WhatsApp Channels| Join now for Breaking News & Editor's Picks

Follow us on :

Follow Us

ADVERTISEMENT
ADVERTISEMENT